Relationship between late arteriovenous fistula (AVF) stenosis and neutrophil–lymphocyte ratio (NLR) in chronic hemodialysis patients

References

• Vachharajani TJ. Diagnosis of arteriovenous fistula dysfunction. Semin Dial. 2012;25(4):445–450
   Google Scholar
• Hayashi R, Huang E, Nissenson AR. Vascular access for hemodialysis. Nat Clin Pract Nephrol. 2006;2(9):504–513
   Google Scholar
• Stolic R. Most important chronic complications of arteriovenous fistulas for hemodialysis. Med Princ Pract. 2013;22(3):220–228
   Google Scholar
• Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17(4):1112–1127
   PubMed Web of Science ®Google Scholar
• Juncos JP, Grande JP, Kang L, et al. MCP-1 contributes to arteriovenous fistula failure. J Am Soc Nephrol. 2011;22(1):43–48
   PubMed Web of Science ®Google Scholar
• Schepers A, Eefting D, Bonta PI, et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2006;26:2063–2069
   PubMed Web of Science ®Google Scholar
• Marrone D, Pertosa G, Simone S, et al. Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis. 2007;49(5):664–673
   PubMed Web of Science ®Google Scholar
• Castellano G, Di Vittorio A, Dalfino G, et al. Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula. Atherosclerosis. 2010;209(1):241–247
   PubMed Web of Science ®Google Scholar
• Roy-Chaudhury P, Khan R, Campos B, et al. Pathogenetic role for early focal macrophage infiltration in a pig model of arteriovenous fistula (AVF) stenosis. J Vasc Access. 2014;15(1):25–28
   Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 2013;33(8):3291–3294
   PubMed Web of Science ®Google Scholar
• Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S. Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/Lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol. 2010;102(7):742–747
   PubMed Web of Science ®Google Scholar
• Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol. 2013;30(3):596
   Web of Science ®Google Scholar
• Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35(4):868–872
   PubMed Web of Science ®Google Scholar
• Motomura T, Shirabe K, Mano Y, et al. Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64
   PubMed Web of Science ®Google Scholar
• Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012;79(5):1085–1091
   PubMed Web of Science ®Google Scholar
• Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23
   PubMed Web of Science ®Google Scholar
• Muhmmed Suliman MA, Bahnacy Juma AA, Ali Almadhani AA, Pathare AV, Alkindi SS, Uwe Werner F. Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome. Arch Med Res. 2010;41(8):618–622
   Google Scholar
• Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111(5):636–642
   PubMed Web of Science ®Google Scholar
• Arbel Y, Finkelstein A, Halkin A, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012;225(2):456–460
   PubMed Web of Science ®Google Scholar
• Turak O, Ozcan F, Isleyen A, et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110(10):1405–1410
   PubMed Web of Science ®Google Scholar
• Tasoglu I, Turak O, Nazli Y, et al. Preoperative neutrophil-lymphocyte ratio and saphenous vein graft patency after coronary artery bypass grafting. Clin Appl Thromb Hemost. 2013. [Epub ahead of print]. DOI: 10.1177/1076029613484086
   Google Scholar
• Dogan M, Akyel A, Cimen T, et al. Relationship between neutrophil-to-lymphocyte ratio and saphenous vein graft disease in patients with coronary bypass. Clin Appl Thromb Hemost. 2013. [Epub ahead of print]. DOI: 10.1177/1076029613488935
   Google Scholar
• Hutchison SJ, Holmes KC, eds. Arteriovenous fistulas. In: Principles of Vascular and Intravascular Ultrasound. Philadelphia: Saunders; 2012:82–96
   Google Scholar
• Clark TW, Hirsch DA, Jindal KJ, Veugelers PJ, LeBlanc J. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas. J Vasc Interv Radiol. 2002;13:51–59
   Google Scholar
• Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation. 1998;97(9):916–931
   PubMed Web of Science ®Google Scholar
• Gagliardi GM, Rossi S, Condino F, et al. Malnutrition, infection and arteriovenous fistula failure: Is there a link? J Vasc Access. 2011;12(1):57–62
   Google Scholar
• Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III8–III14
   PubMed Web of Science ®Google Scholar
• Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403. doi: 10.1155/2013/891403
   Google Scholar